About Vernalis Therapeutics

Headquartered in Berwyn PA, Vernalis Therapeutics, Inc. is a US subsidiary of Vernalis plc, established to commercialize extended-release formulations of prescription products for the US market. These products are being developed in partnership with New Jersey based Tris Pharma, Inc.

The NDA for the lead product, Tuzistra® XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII, was approved by the FDA on 30 April 2015 and the product was launched into the 2015/2016 cough cold season. Click here for full Prescribing Information for Tuzistra® XR, including Boxed Warning and here for the Medication Guide.

In October 2015, Vernalis also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older. Click here for full Prescribing Information for Moxatag®.

Vernalis Therapeutics, Inc. takes its responsibility as a pharmaceutical company seriously promoting and supporting a culture of integrity and compliance. 

Latest News

AGM Statement

Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & Burling, 265 Strand, London WC2R 1BH.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch